APASL consensus statements and recommendation on treatment of hepatitis C

doi:10.1007/s12072-016-9717-6

Review

. 2016 Sep;10(5):702-26.

doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29.

APASL consensus statements and recommendation on treatment of hepatitis C

Masao Omata^{1

2}, Tatsuo Kanda³, Lai Wei⁴, Ming-Lung Yu⁵, Wang-Long Chuang⁶, Alaaeldin Ibrahim⁷, Cosmas Rinaldi Adithya Lesmana⁸, Jose Sollano⁹, Manoj Kumar¹⁰, Ankur Jindal¹⁰, Barjesh Chander Sharma¹¹, Saeed S Hamid¹², A Kadir Dokmeci¹³, Mamun-Al-Mahtab¹⁴, Geofferey W McCaughan¹⁵, Jafri Wasim¹², Darrell H G Crawford¹⁶, Jia-Horng Kao¹⁷, Osamu Yokosuka³, George K K Lau¹⁸, Shiv Kumar Sarin¹⁰

Affiliations

¹ Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-Shi, Yamanashi, 400-8506, Japan. hepint_omata@yahoo.co.jp.
² The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hepint_omata@yahoo.co.jp.
³ Graduate School of Medicine, Chiba University, Chiba, Japan.
⁴ Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
⁵ Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
⁶ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ GI/Liver Division, Department of Internal Medicine, University of Benha, Benha, Egypt.
⁸ Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia.
⁹ University Santo Tomas Hospital, Manila, Philippines.
¹⁰ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
¹¹ Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
¹² Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan.
¹³ Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
¹⁴ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh.
¹⁵ Centenary Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
¹⁶ School of Medicine, University of Queensland, Woolloongabba, QLD, 4102, Australia.
¹⁷ National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
¹⁸ The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

PMID: 27130427
PMCID: PMC5003907
DOI: 10.1007/s12072-016-9717-6

Review

APASL consensus statements and recommendation on treatment of hepatitis C

Masao Omata et al. Hepatol Int. 2016 Sep.

. 2016 Sep;10(5):702-26.

doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29.

Authors

Affiliations

¹ Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-Shi, Yamanashi, 400-8506, Japan. hepint_omata@yahoo.co.jp.
² The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hepint_omata@yahoo.co.jp.
³ Graduate School of Medicine, Chiba University, Chiba, Japan.
⁴ Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
⁵ Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
⁶ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ GI/Liver Division, Department of Internal Medicine, University of Benha, Benha, Egypt.
⁸ Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia.
⁹ University Santo Tomas Hospital, Manila, Philippines.
¹⁰ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
¹¹ Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
¹² Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan.
¹³ Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
¹⁴ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh.
¹⁵ Centenary Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
¹⁶ School of Medicine, University of Queensland, Woolloongabba, QLD, 4102, Australia.
¹⁷ National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
¹⁸ The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

PMID: 27130427
PMCID: PMC5003907
DOI: 10.1007/s12072-016-9717-6

Abstract

The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.

Keywords: APASL; DAAs; HCV; Interferon-free; Turkey.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical statements Conflict of interest All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. This article does not contain any studies with animal subjects. Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, Alaaeldin Ibrahim, George K. K.Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell HG Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences and Abbvie, and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche, and consulting fee from Abbott, Abbvie, BMS, Gilead and Novartis. Ming-Lung Yu is the consultant, advise board member and have grant support from Abbvie, BMS, Gilead, ROCHE, MSD and Abbott. Wang-Long Chuang has speaker fees from Gilead, BMS, MSD, Roche and Novartis, and is a member of Advisory Board: Gilead, Abbvie and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences and Roche, and has also served on speaker’s bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb, and received speakers fees from Merck Sharp & Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co, GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute.

Figures

**Fig. 1**
Sustained virological response (*SVR*) rates (%) of daily ledipasvir (*LDV*) and sofosbuvir (*SOF*). a Treatment-naïve patients with HCV genotype 1, b Treatment-experienced patients with HCV genotype 1

**Fig. 2**
Treatment for HCV genotype-1 in Asian-Pacific region

See this image and copyright information in PMC

Cited by

Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection.
Liu CH, Liu CJ, Su TH, Huang SC, Tseng TC, Wu JH, Chen PJ, Kao JH. Liu CH, et al. Diagnostics (Basel). 2022 Oct 31;12(11):2650. doi: 10.3390/diagnostics12112650. Diagnostics (Basel). 2022. PMID: 36359492 Free PMC article.
Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China.
Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Lei JH, et al. Arch Med Sci. 2018 Aug;14(5):1055-1060. doi: 10.5114/aoms.2017.70664. Epub 2017 Oct 12. Arch Med Sci. 2018. PMID: 30154888 Free PMC article.
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.
Ko SY, Choe WH. Ko SY, et al. Clin Mol Hepatol. 2018 Dec;24(4):351-357. doi: 10.3350/cmh.2017.0063. Epub 2018 Mar 16. Clin Mol Hepatol. 2018. PMID: 29544240 Free PMC article. Review.
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Asselah T, et al. PLoS One. 2017 Jan 5;12(1):e0168713. doi: 10.1371/journal.pone.0168713. eCollection 2017. PLoS One. 2017. PMID: 28056030 Free PMC article. Clinical Trial.
Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Wang XX, Luo BF, Jiang HJ, Cong X, Jin Q, Ma DL, Wei L, Feng B. Wang XX, et al. World J Gastroenterol. 2018 Oct 28;24(40):4554-4564. doi: 10.3748/wjg.v24.i40.4554. World J Gastroenterol. 2018. PMID: 30386105 Free PMC article.

See all "Cited by" articles

References

1. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409–435. doi: 10.1007/s12072-012-9342-y. - DOI - PubMed
1. Asian-Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R Asian-Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615–633. doi: 10.1111/j.1440-1746.2007.04883.x. - DOI - PubMed
1. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548–561. doi: 10.1007/s12072-010-9193-3. - DOI - PMC - PubMed
1. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993–999. doi: 10.1016/j.jhep.2004.02.007. - DOI - PubMed
1. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–2617. doi: 10.1056/NEJMoa042608. - DOI - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409–435. doi: 10.1007/s12072-012-9342-y. - DOI - PubMed

[2] Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409–435. doi: 10.1007/s12072-012-9342-y. - DOI - PubMed

[3] Asian-Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R Asian-Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615–633. doi: 10.1111/j.1440-1746.2007.04883.x. - DOI - PubMed

[4] Asian-Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R Asian-Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615–633. doi: 10.1111/j.1440-1746.2007.04883.x. - DOI - PubMed

[5] Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548–561. doi: 10.1007/s12072-010-9193-3. - DOI - PMC - PubMed

[6] Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548–561. doi: 10.1007/s12072-010-9193-3. - DOI - PMC - PubMed

[7] Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993–999. doi: 10.1016/j.jhep.2004.02.007. - DOI - PubMed

[8] Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993–999. doi: 10.1016/j.jhep.2004.02.007. - DOI - PubMed

[9] Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–2617. doi: 10.1056/NEJMoa042608. - DOI - PubMed

[10] Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–2617. doi: 10.1056/NEJMoa042608. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

APASL consensus statements and recommendation on treatment of hepatitis C

Affiliations

APASL consensus statements and recommendation on treatment of hepatitis C

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources